Adriatic Metals release positive assay results

|

Published 22-JUN-2018 14:01 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Finfeed presents this information for the use of readers in their decision to engage with this stock. Please be aware that this is a very high risk stock. We stress that this article should only be used as one part of this decision making process. You need to fully inform yourself of all factors and information relating to this product before engaging with it.

Zinc polymetallic explorer Adriatic Metals (ASX:ADT) has received assay results from its second completed drillhole as it continues its 15,000 metre drilling program at Rupice North.

Rupice North is part of ADT’s zinc polymetallic Vareš Project located in Bosnia and Herzegovina.

The Vareš Project comprises a historic open cut zinc/lead/barite and silver mine at Veovaca and Rupice. The project has shown exceptionally high-grades of base and precious metals.

Adriatic’s short-term aim is to expand the current JORC resource at Veovaca and to complete an in-fill drilling program at the high-grade Rupice deposit.

It still has some way to go to meet these aims, so investors should seek professional financial advice if considering this stock for their portfolio.

It has gone some way to meeting its Rupice ambitions with the release of today’s assay results.

Drilling has returned high grade and thick intercepts north of the current zone of mineralisation.

Results include:

  • 36m @ 4.4 g/t Au, 463g/t Ag, 0.5% Cu, 4.3% Pb, 5.7% Zn, 55% BaSO4from 196m (BR-3-18), and
  • 22m @ 4.1 g/t Au, 258g/t Ag, 0.8% Cu, 7.5% Pb, 12.8% Zn, 56% BaSO4from 244m (BR-3-18).

The second hole, drill hole BR-3-18, was drilled in a south-westerly direction at -60 ̊ to test the down dip and down plunge extension of the high-grade mineralisation intersected in ADT’s first drill hole of its 2018 drilling program – BR-2-18.

The intersection represents an 80m down dip extension from the 2017 drilled BR-5-17. ADT is currently drilling BR-5-18 which is collared a further 30m north of BR-3-18.

Current drilling is designed to test the northerly extensions of the Rupice North mineralisation where no historical drilling has ever been conducted.

In BR-3-18, the mineralisation occurs as two high grade lenses, separated by 12m of weakly mineralised breccia. The upper intersection is 36m thick and the lower intersection 22m thick and both show increasing lead and zinc grades with depth.

The BR-3-18 mineralisation is very visible and consists of galena, sphalerite, chalcopyrite and barite. The minersalised zone is highlighted in the map below:

ADT CEO Geraint Harris commented, “BR-3-18 represents another significant extension to the north and notably down dip at the Rupice North Zone. As we continue to step out our drilling, we significantly expand our knowledge of this very exciting thick and highly mineralised zone, which remains wide open in several directions. Our current drill program is advancing well, and the early results have been quite spectacular, both in terms of grade, thickness and extension. We continue to drill, both at the Rupice North Zone and the JB Zone, and look forward to updating our shareholders on further results in due course.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X